Comparable stake leader
Robert Crotty
SEC ownership of Nabriva Therapeutics plc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001641640.
Disclosed value leader
Robert Crotty
Comparable rows
0/13
Latest evidence
29 Jan 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Robert Crotty
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
29 Jan 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001641640
- Issuer location
- Dublin, Ireland
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Nabriva Therapeutics plc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Robert Crotty
Disclosed value leader
Robert Crotty
Comparable rows
0/13
Latest evidence
29 Jan 2023
3/4/5
Highest disclosed value: $61,791
13 rows are not safely comparable across share classes.
Showing 1-8 of 13 holder rows.
Quick read
Robert Crotty has the largest disclosed position value at $61.8K.
0 of 13 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Robert Crotty's linked filing trail.
Disclosed position value
Top 5
Robert Crotty
$61.8K
Colin Broom MD
$54.8K
Charles A. Rowland Jr.
$22.9K
Steven P. Gelone
$21.4K
Theodore R. Schroeder
$18K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 13 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Robert Crotty |
3/4/5
Gen Counsel & Corp Secretary
|
—
denominator unverified
|
$61,791
41,194 shares
|
— | 31 Aug 2021 |
| Colin Broom MD |
3/4/5
Director
|
—
denominator unverified
|
$54,785
36,523 shares
|
— | 02 Aug 2022 |
| Charles A. Rowland Jr. |
3/4/5
Director
|
—
denominator unverified
|
$22,916
15,277 shares
|
— | 02 Aug 2021 |
| Steven P. Gelone |
3/4/5
Director
|
—
denominator unverified
|
$21,425
14,283 shares
|
— | 29 Jan 2023 |
| Theodore R. Schroeder |
3/4/5
Director
|
—
denominator unverified
|
$17,984
11,989 shares
|
— | 29 Jan 2023 |
| Stephen W. Webster |
3/4/5
Director
|
—
denominator unverified
|
$17,171
11,447 shares
|
— | 02 Aug 2022 |
| Daniel D. Burgess |
3/4/5
Director
|
—
denominator unverified
|
$15,576
10,384 shares
|
— | 02 Aug 2022 |
| Carrie L. Bourdow |
3/4/5
Director
|
—
denominator unverified
|
$14,900
9,933 shares
|
— | 01 Aug 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 21 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Nabriva Therapeutics plc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Robert Crotty
Net 12M change
$0
Latest report
06 Jul 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Robert Crotty | Gen Counsel & Corp Secretary | $61,791 | Mixed | 31 Aug 2021 | ||
| Colin Broom MD | Director | $54,785 | Mixed | 02 Aug 2022 | ||
| Charles A. Rowland Jr. | Director | $22,916 | Mixed | 02 Aug 2021 | ||
| Steven P. Gelone | Director | $21,425 | Mixed | 29 Jan 2023 | ||
| Theodore R. Schroeder | Director | $17,984 | Mixed | 29 Jan 2023 | ||
| Stephen W. Webster | Director | $17,171 | Mixed | 02 Aug 2022 | ||
| Daniel D. Burgess | Director | $15,576 | Mixed | 02 Aug 2022 | ||
| Carrie L. Bourdow | Director | $14,900 | Mixed | 01 Aug 2022 | ||
| Lisa Dalton | Director | $13,650 | Mixed | 31 Jul 2022 | ||
| Mark Corrigan | Director | $10,805 | Mixed | 02 Aug 2022 | ||
| David Maggio | Chief Financial Officer | Mixed | 30 Jun 2023 | |||
| H. Michael Hogan III | Chief Executive Officer | Mixed | 06 Jul 2023 | |||
| J. Christopher Naftzger | General Counsel and Corp Sec | Mixed | 11 Aug 2022 | |||
| J. Guico Pabia | Chief Medical Officer | Mixed | 11 Aug 2022 | |||
| Daniel Dolan | Chief Financial Officer | Mixed | 11 Aug 2022 |
Recent insider transactions for Nabriva Therapeutics plc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.